Top Story

Pfizer responds to NICE ACD For MYLOTARG™▼

Pfizer comments on NICE appraisal for MYLOTARG™▼ (gemtuzumab ozogamicin)

Read more

AbbVie have announced that the Phase 3 iLLUMINATE trial met its primary endpoint...

Read more

Alantra Pharma Fast 50, an annual ranking of non-listed UK pharmaceutical companies...

Read more

Alantra Pharma Fast 50, an annual ranking of non-listed UK pharmaceutical companies...

Read more

Sue Mahony senior vice president of Lilly and president of Lilly Oncology to retire...

Read more

the European Commission (EC) has approved Zessly® (infliximab) for use in Europe....

Read more

CombiGene granted 3,3 million euro in latest Phase 2 round in the Horizon 2020 SME Instrument progra...

Read more

ABPI response to Government commitment to £30million to fight global antimicrobial resistance...

Read more

Lilly's Taltz® Receives FDA Approval for Label Update to Include Data for Genital Area Psoriasis...

Read more

Survey results demonstrate the need for more support and control in their own haemophilia care...

Read more

New study in Obesity reveals metabolic phenotypes described by skewed body fat distributions...

Read more